Stockreport

Kura Oncology: A Contender In The Field Of Precision Medicine [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a potentially unlocking a $3 billion market in the U.S. [Read more]